Dermira’s QBREXZA (glycopyrronium) Cloth Is Now Available in Pharmacies Nationwide

Dermira (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin conditions, announced today that QBREXZA (glycopyrronium) cloth is now available for prescribing to treat primary axillary hyperhidrosis, commonly known as excessive underarm sweating.

As quoted in the press release:

The new therapy is available in retail and community pharmacies nationwide. In June 2018, QBREXZA, a once-daily, prescription anticholinergic, was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients 9 years of age and older living with this chronic, medical skin condition.

“People living with primary axillary hyperhidrosis often report feelings of isolation, and struggle in silence for years before finally speaking to a healthcare professional. In most instances, people are often too embarrassed to seek treatment, and when they do, they may not find solutions that effectively control their excessive underarm sweating,” said Lisa J. Pieretti, Executive Director for the International Hyperhidrosis Society and a patient advocate for more than 15 years. “The availability of QBREXZA represents an FDA-approved, topical medicine for the millions of adults and children who may be looking for a new way to treat their excessive underarm sweating. It is my hope that many of these sufferers will finally get the sweat help they have been seeking much of their lives.”

Click here to read the full press release.